Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib in Metastatic Urothelial Carcinoma
NCT01551030Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2012
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in urothelial carcinoma (UC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Progression Free Survival at 2 months and Progression Free Survival in the Expansion Cohort up to 16 months. Started Mar 2012; status: completed.
02
Drugs
buparlisib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01551030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01551030.